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Bovine viral diarrhea virus (BVDV) is a member of the genus Pestivirus within the family
Flaviviridae. BVDV causes both acute and persistent infections in cattle, leading to
substantial financial losses to the livestock industry each year. The global prevalence of
persistent BVDV infection and the lack of a highly effective antiviral therapy have spurred
intensive efforts to discover and develop novel anti-BVDV therapies in the pharmaceutical
industry. Antiviral targeting of virus envelope proteins is an effective strategy for
therapeutic intervention of viral infections. We performed prospective small-molecule
high-throughput docking to identify molecules that likely bind to the region delimited
by domains I and II of the envelope protein E2 of BVDV. Several structurally different
compounds were purchased or synthesized, and assayed for antiviral activity against
BVDV. Five of the selected compounds were active displaying IC50 values in the low- to
mid-micromolar range. For these compounds, their possible binding determinants were
characterized by molecular dynamics simulations. A common pattern of interactions
between active molecules and aminoacid residues in the binding site in E2 was observed.
These findings could offer a better understanding of the interaction of BVDV E2with these
inhibitors, as well as benefit the discovery of novel and more potent BVDV antivirals.
Keywords: BVDV entry inhibitors, structure-based virtual screening, molecular dynamics simulation, envelope
protein, molecular docking
INTRODUCTION
Bovine viral diarrhea virus (BVDV) is a worldwide distributed pathogen of cattle. Together with
classical swine fever virus (CSFV) and border disease virus (BDV) of sheep, BVDV belongs to the
genus Pestivirus of the Flaviviridae family. The pestiviral genome is a positive, single-stranded
RNA molecule of about 12.3 kb in length encoding a single polyprotein that is processed into
individual viral proteins: Npro -C-Erns -E1-E2-p7-NS2-NS3-NS4A-NS4B-NS5A-NS5B (Collett
et al., 1988). Pestivirus particles consist of a lipid bilayer with envelope glycoproteins Erns, E1,
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and E2 surrounding the nucleocapsid, composed by the capsid
protein C and the RNA genome (Callens et al., 2016). BVDV
infection is distributed worldwide resulting in major economic
losses to the livestock industry. The virus is primarily a pathogen
of cattle and the clinical manifestations are presented as acute
infection, fetal infection, or mucosal disease (Lanyon et al., 2014).
Based on genetic and antigenic differences, BVDV is segregated
into genotypes 1 and 2. For each of these genotypes, cytopathic
and non-cytopathic biotypes are distinguished according to
the capacity of virus infection to induce cell death in culture
(Ridpath, 2003). Non cytopathic (ncp) BVDV biotypes cause
acute infections in adult animals and can be transmitted across
the placenta to the fetus. Fetal infection is particularly relevant
and it can lead to congenital malformations and abortion, or
to the birth of persistently infected (PI) calves that spread
and maintain the disease in cattle populations (Lanyon et al.,
2014). Cytopathic (cp) BVDV biotypes arise in PI cattle from
recombination events in the infecting ncpBVDV genome, and are
associated with the development of fatal mucosal disease (Becher
and Tautz, 2011).
Control and prevention of BVDV infection should combine
systematic vaccination with detection and culling of persistently
infected cattle from herds (Newcomer and Givens, 2013).
However, immunization is complicated due to the wide
antigenic diversity of the virus, and fails to target the
emergence of persistently infected animals (Fulton et al., 2003;
Newcomer et al., 2017). Previous studies showed that antivirals
directed against the pestivirus polymerase NS5B provide
immediate protection from viral challenge (Newcomer et al.,
2012), thus prophylactic treatment with antivirals represents
an alternative for therapeutic intervention in outbreaks of
BVDV.
Computer-aided drug design has become an integral part
of drug discovery and development in the pharmaceutical
and biotechnology industry, and is nowadays extensively used
in lead identification and optimization (Cavasotto and Orry,
2007; Jorgensen, 2009; Spyrakis and Cavasotto, 2015). Virus
envelope proteins are attractive targets for the development
of antiviral agents, and structure-based drug design has been
successfully used to identify small molecule ligands of envelope
proteins that block entry of flaviviruses (Zhou et al., 2008;
Kampmann et al., 2009; Leal et al., 2017). With the aim of
finding novel targets for pestivirus drug design, we focused
on the in silico identification of antivirals directed against the
envelope protein E2 of BVDV. E2 mediates receptor recognition
on the cell surface and is required for fusion of virus and
cell membranes after the endocytic uptake of the virus during
entry (Ronecker et al., 2008; Wang et al., 2009). In this work,
we expand on a structure-based approach to seek hit small-
molecules that dock into the druggable pocket at the interface
between domains I and II of the envelope protein E2 of
BVDV (Pascual et al., 2018). Around a million compounds
from different chemical libraries were screened in a high-
throughput docking (HTD) fashion. This led to the selection
of nineteen lead candidates that were either purchased or
synthesized, and evaluated in a reporter-based assay for antiviral
activity. The likely interaction of active compounds with the
protein E2 was further characterized by molecular dynamics
(MD) simulations. The approach presented here led to the
identification of five of novel compounds with anti-BVDV
activity displaying IC50 values in the low to mid-micromolar
range.
MATERIALS AND METHODS
Computational Chemistry
Molecular System Preparation
All simulations were based on the crystal structure of the
pestivirus of the envelope glycoprotein E2 from BVDV (PDB
2YQ2) (El Omari et al., 2013). Protein domains were designated
from the N- to the C-terminus of E2 as I, II and III according
to the nomenclature used by Li et al. (2013). The molecular
system was described in terms of torsional coordinates using
the ECEPP/3 force field (Nemethy et al., 1992) as implemented
in the ICM program (version 3.7-2c, MolSoft LLC, La Jolla,
CA; Abagyan et al., 1994), and prepared in a similar fashion
as earlier works (He et al., 2012; Brand et al., 2013; Leal et al.,
2017; Pascual et al., 2018). Hydrogen atoms were added to
the receptor structure followed by local energy minimization.
All Asp and Glu residues were assigned a −1 charge, and all
Arg and Lys residues were assigned a +1 charge. Histidine
tautomers were assigned according to the hydrogen bonding
pattern.
High-Throughput Docking
As in an earlier work (Pascual et al., 2018), docking was
performed within Site I located at the interface of domains I
and II of E2. All water molecules and co-factors were deleted.
A flexible-ligand:rigid-receptor docking methodology as
implemented in ICM was used. The receptor was represented
by six potential energy maps, while the docked molecule
was considered flexible and subjected to global energy
minimization within the field of the receptor using a
Monte Carlo protocol (Abagyan et al., 1994; Cavasotto
et al., 2006); thus, the intra- and inter-molecular energy of
the molecule are minimized. Each molecule was assigned
an empirical docking score according to its fit within the
binding site (Totrov et al., 2001). Two independent runs of
HTD were performed to improve convergence of the global
optimization energy, while the best score per molecule was
kept.
Small-Molecule Libraries and Filtering
The ZINC (Irwin and Shoichet, 2005) (accessed Nov. 2014),
Maybridge (http://www.maybridge.com/), and in house
databases were chosen for HTD. They were first filtered to
remove the compounds containing inorganic atoms, PAINS
(Filtering Pan-assay interfering substances) structures, and
other reactive groups. Then the complete virtual library was
pre-filtered for properties based on Lipinski’s rules (Lipinski
et al., 1997). Finally about a total of one million small-
molecules were used. The PAINS filter was implemented
through the online server FAF-Drugs3 (Lagorce et al.,
2015).
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FIGURE 1 | Chemical structures of the 19 hits from docking-based virtual screening.
Molecular Dynamics
MD simulations were performed using GROMACS v5.1 package
(Abraham et al., 2015) using the Amber99SB force field (Hornak
et al., 2006). The system was solvated with the SPCE water
model in a triclinic box, extending 10 Å from the protein, and
neutralized adding sufficient NaCl counter ions to reach 0.15M
concentration. Bond lengths were constrained using the LINCS
algorithm allowing a 2 fs time-step. Long-range electrostatics
interactions were taken into account using the particle-mesh
Ewald (PME) approach. The non-bonded cut-off for Coulomb
and Van der Waals interactions were both 10 Å, and the non-
bonded pair list was updated every 25 fs. Energy minimization
was conducted through the steepest-descent algorithm, until
the maximum force decayed to 1,000 [kJ mol−1 nm−1]. Then
an equilibration of the whole system was performed by 500
ps of NVT simulation followed by 500 ps of NPT simulation.
Temperature was kept constant at 300K using a modified
Berendsen thermostat (Berendsen et al., 1984) with a coupling
constant of 0.1 ps. Constant pressure of 1 bar was applied
in all directions with a coupling constant of 2.0 ps and a
compressibility of 4.5 10−5 bar−1.
Biological Evaluation
Cell Culture
MDBK cells (Bos taurus kidney, ATCC CCL-22) were purchased
from ATCC and grown in Dulbecso’s modified Eagle medium
(DMEM) supplemented with 10% fetal bovine serum and
antibiotics under 5% CO2 at 37◦C. For infections, cells were
cultivated in DMEM supplemented with 2% Horse serum and
antibiotics under 5% CO2 at 37◦C.
Cytotoxicity Assay
Cell viability assays were performed on confluent cell cultures
in 96 well plates (∼15,000 cells per well). For each compound,
cells were treated with serial dilutions of the compound in
quadruplicates and incubated at 37◦C for 3 days. Then, cell
viability was measured using crystal violet staining. Briefly, cells
were fixed with 10% formaldehyde, stained with crystal violet
solution (20% Ethanol, 0.1% Crystal Violet), and after washing,
the absorbance at 595 nm was recorded for each well in a
spectrophotometer. Assays were conducted at least in duplicates,
and the cytotoxic concentration 50 (CC50) was estimated by a
nonlinear regression fitting of five data points as the compound
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TABLE 1 | Antiviral activity against BVDV.
Compound IC50(µM)
a BVDV CC50 (µM)
b
1 NA >50
2 44.3 ± 10.3 >50
3 NA >50
4 30.1 ± 2.9 >50
5 NA >50
6 ND 7.2 ± 1.3
7 NA >50
8 20.2 ± 3.6 >50
9 NA >50
10 NA >50
11 23.9 ± 7.9 >50
12 44.4 ± 11.5 >50
13 NA 61.5±1.4
14 NA >50
15 NA >50
16 NA 49.8 ± 1.5
17 NA >50
BI03c 17.6 ± 6.4 >200
PTC12c 0.30 ± 0.10 89.5 ± 1.1
a IC50: inhibitory concentration 50%. Data represent the mean and standard deviation of
at least two independent experiments.
bCC50: cytotoxic concentration 50%. Data represent the mean and standard deviation of
at least two independent experiments.
cPascual et al. (2018).
NA indicates assayed but not active compounds; ND Not determined.
concentration necessary to reduce cell viability by 50% compared
to control non-treated cells.
Reporter-Based Assay for Antiviral Activity
Antiviral activity was evaluated in a reporter-based assay using a
recombinant virus expressing GFP, cpBVDV/Npro GFP (Pascual
et al., 2018). MDBK cells were seeded onto 24 well plates, infected
with cpBVDV/Npro GFP at a multiplicity of infection of 0.1
in the presence of increasing concentrations of compounds. At
48 h post-infection cells were thoroughly washed, lifted with
trypsin 0.05% and fixed using 4% paraformaldehyde in PBS.
The fluorescence signal was measured using a flow cytometer
(CyFlow R© Space, Partec) at a detection spectrum of 488 nm.
Data were analyzed in the FlowJo 7.6.2 software package. The
inhibitory concentrations 50 (IC50s) for the compounds tested
in the assay were calculated from curves constructed by plotting
the percentage of infected cells versus the concentration of
compound as the compound concentration necessary to reduce
the number of infected cells by 50% compared to control non-
treated cells.
Chemistry
General Information
NMR spectra were recorded on Bruker Biospin 600 MHz
AVIII600, Bruker advance II 500 MHZ and Bruker 300 MHZ
spectrometers at room temperature. Chemical shifts (δ) are
reported in ppm and coupling constants (J) in Hertz. Column
chromatography was carried out employing Merck silica gel
(Kieselgel 60, 63–200µm). Precoated silica gel plates F-254
were used for thin-layer analytical chromatography. The
mass spectrometer utilized was a Xevo G2S QTOF (Waters
Corporation, Manchester, UK) with an electrospray ionization
(ESI) source. The mass spectrometer was operated in positive
and negative ion modes with probe capillary voltages of 2.5 and
2.3 kV, respectively. The purity (≥95%) of all final synthesized
compounds was determined by reverse phase HPLC, using a
Waters 2487 dual λ absorbance detector with a Waters 1,525
binary pump and a Phenomenex Luna 5µ C18(2) 250× 4.6mm
column. Samples were run at 1 mL/min using gradient mixtures
of 5–100% of water with 0.1% trifluoroacetic acid (TFA) (A) and
10:1 acetonitrile:water with 0.1% TFA (B) for 22min followed by
3min at 100% B. UV spectra were measured with a Shimadzu
3600 UV/vis/NIR spectrophotometer.
Synthetic Procedures of New Compounds From Our
in House Library
Synthesis of (E)-2-(4-(dimethylamino)benzylidene)-N-(4-
(trifluoromethyl)phenyl)hydrazinecarbothioamide (11)
Synthesis of N-(4-trifluoromethoxyphenyl)hydrazinecarbothioa
mide (19) Sodium hydroxide (0.14 g, 3.4 mmol) and carbon
disulphide (0.2mL, 2.8 mmol) were added to a solution of 4-
(trifluoromethoxy)aniline 18 (0.50 g, 2.8 mmol) in DMF (5mL).
The mixture was stirred at room temperature for 1 h. Then,
hydrazine hydrate (0.5mL, 8.5 mmol) was added and stirring
continued at 70◦C for 1 h. After water addition compound
19 precipitate and the solid was filtrated off. The crude was
recristallized from ethanol:water (0.28 g, 39.1 %). 1H NMR (500
MHz, CDCl3) δ 9.30 (s, 1H), 7.82 (s, 1H), 7.68 (d, J = 7.1Hz,
2H), 7.24 (d, J = 8.7Hz, 2H), 4.01 (s, 2H). To a solution
of 19 (0.10 g; 0.40 mmol) in ethanol (3mL) was added 4-
dimethylaminobenzaldehyde (0. 65 g, 0.44 mmol). The mixture
was stirred under reflux for 1 h. The reaction was then cooled
to room temperature, and precipitate solid was filtered and
washed with cyclohexane to give 11, which was recristallized
from ethanol. (0.07 g, 43.5 %). 1H NMR (600 MHz, CDCl3) δ
9.37 (s, 1H), 9.20 (s, 1H), 7.79 (s, 1H), 7.76 (dd, J = 8.9, 2.1Hz,
2H), 7.57 (dd, J = 8.9, 2.1Hz, 2H), 7.27 (d, J = 8.5Hz, 2H),
6.72 (dd, J = 8.9, 1.9Hz, 2H), 3.07 (s, 6H). 13C NMR (151 MHz,
CDCl3) δ 175.2, 152.2, 146.5, 144.2, 144.1, 136.75, 129.0, 125.4,
125.3, 121.3, 121.2, 121.2, 120.1, 119.6, 111.8, 111.7, 40.1, 40.09.
HR-MS (ES) calcd for C17H18F3N4OS [M+H]+ 383.1153, found
383.1141.
4-((5-methylisoxazol-3-yl)amino)-4-oxobutanoic acid. (14)
To a solution of isoxazol-5-amine (0.20 g, 2.0 mmol) 20 in
dioxane (5mL) was added succinic anhydride (0.20 g, 2.0 mmol).
The mixture was stirred at 80–90◦C overnight. The solvent was
evaporated and the obtained yellowish solid was suspended in
water, collected by filtration, and crystallized from ethanol to
give the pure product as a white solid (0.088 g, 0.44 mmol,
22%). 1H NMR (600 MHz, dmso-d6) δ 12.14 (s, 1H), 10.87
(s, 1H), 6.58 (s, 1H), 2.55 (t, J = 6.5Hz, 2H), 2.34 (s, 3H). The
other methylene group was determined by HSQC, due to the
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SCHEME 1 | Synthesis of compound 11. Reagents and conditions. (a) CS2, NaOH, DMF, 25
◦C, 1 h. NH2NH2, 70
◦C, 1 h. (b) 4-dimethylaminobenzaldehyde, EtOH,
Reflux, 1 h.
SCHEME 2 | Synthesis of compound 15 and 16. Reagents and conditions. (a) SOCl2, TEA, DCM, N2, rt, 5 h; (b) Cs2CO3, ACN, rt, overnight; (c)
4-(trifluoromethoxy)aniline, TEA, DCM, rt, overnight; (d) dioxane 80–90◦C, 5 h.
overlapping with solvent signal (SI). 13C NMR (151 MHz, dmso-
d6): δ 173.4, 170.3, 169.2, 158.1, 96.2, 30.4, 28.4, 12.1. HRMS
(ES) m/z calc. for C8H10N2O4Na [M+Na]+: 221.0538; found:
221.0533, C8H11N2O4 [M+H]+: 119.0719; found: 199.0714.
4-chloro-N-(isoxazol-5-yl)benzamide (15)
A mixture of p-chloro benzoic acid (1.0 g, 6.4 mmol), and an
excess of thionyl chloride (4.92 g, 3mL, 41.7 mmol) was refluxed
for 2 h. The excess of thionyl chloride was distilled in vacuo
and the acyl chloride was used without further purification. To
a solution of p-chlorobenzoyl chloride 23 in MeCN (10mL)
was added Cs2CO3 (3.7 g, 19 mmol) and isoxazol-5-amine 20
(0.63 g, 6.4 mmol) at 0◦C and the obtained suspension was stirred
at r.t. overnight. Then, the reaction mixture was concentrated
under vacuo and the obtained residue was treated with water
and extracted with EtOAc (4 × 20mL). The organic layers
were dried over Na2SO4, filtered-off and concentrated under
vacuo to give a residue that was purified by silica gel column
chromatography eluting with cHex/EtOAc (95:5–70:30). The
product was obtained as a white solid (0.146 g, 0.63 mmol, 10%).
FIGURE 2 | Ribbon representation of protein E2 with PTC12 ligand within the
binding site. Figure prepared with ICM (MolSoft LLC, La Jolla, CA).
1HNMR (600MHz, dmso-d6) δ 11.39 (s, 1H), 8.02 (d, J = 8.6Hz,
2H), 7.60 (d, J = 8.6Hz, 2H), 6.74 (s, 1H), 2.41 (s, 3H). 13C NMR
(151 MHz, dmso-d6) δ 169.4, 164.2, 158.5, 137.1, 131.9, 129.9,
128.5, 96.9, 12.1. HRMS (ES) m/z calc. for C11H9ClN2O2Na
[M+Na]+: 259.0250; found: 259.0247, C11H10ClN2O2 [M+H]+
237.0431; found: 237.0428.
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FIGURE 3 | Predicted interaction of active compounds PTC12 (A), BI03 (B), 11 (C), and 8 (D) within the E2 protein binding site, extracted from the molecular
dynamics simulations. For simplicity, only aminoacids within 4 Å of the ligand and polar hydrogens are shown. Hydrogen bonds are shown as a line of orange colored
spheres. Color code: ligand carbons, yellow; E2 protein carbons, white; oxygens, red; nitrogens, blue; sulfur, dark yellow; polar hydrogens, dark gray. Figure prepared
with ICM (MolSoft LLC, La Jolla, CA).
N-(4-(trifluoromethoxy)phenyl)furan-2-carboxamide (16)
Thionyl chloride (0.1mL, 1.34 mmol) was added dropwise
to a mixture of 2-furoic acid 20 (0.15 g, 1.34 mmol) and
triethylamine (0.26mL, 1.82 mmol) in DCM (5mL) under
N2 atmosphere. The reaction mixture was stirred at room
temperature for 5 h. The crude was added to another flask
containing 4-(trifluoromethoxy)aniline (0.16mL, 1.22 mmol)
and triethylamine (0.34mL, 2.43 mmol) in DCM (5mL).
The reaction mixture was stirred at room temperature
overnight. After complete reaction, the solvent was the removed
under reduced pressure, water added and extracted with
dichloromethane. The organic layer was sequentially washed
with brine, dried over anhydrous Na2SO4 and concentrated
in vacuo. The crude was purified by column chromatography
(SiO2, dichloromethane) to give a white solid 16 (0.25 g, 75.6 %).
1H NMR (600 MHz, DMSO-d6) δ 10.38 (s, 1H), 7.96 (d, J =
0.9Hz, 1H), 7.88 (dd, J = 9.1, 2.0Hz, 2H), 7.40–7.32 (m, 3H),
6.72 (dd, J = 3.4, 1.7Hz, 1H). 13C NMR (126 MHz, CDCl3)
δ 156.0, 147.4, 145.4, 144.3, 136.0, 121.8, 121.5, 121.0, 119.4,
115.6, 112.7. HR-MS (ES) calcd for C12H8F3NO3Na [M+Na]+
294.0354, found 294.0345. Synthetic procedure of compounds 5,
12, 13 and 17 from the ZINC library are described in Supporting
information (Scheme S1 and S2).
RESULTS AND DISCUSSION
Computer-Aided Indentification, Chemical
Synthesis, and Biological Evaluation of
Novel Inhibitors
We employed a multistep HTD screening framework to
efficiently identify novel inhibitors of the E2 protein using
commercially available (ZINC andMaybridge chemical libraries)
and synthetic druglike compounds (from our in house library)
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FIGURE 4 | Time dependence of hydrogen bond (HB) distances between (A) the carbonyl O of Gln89 and the benzamide H of PTC12 ligand, and (B) the backbone
amide H of Thr60 and the N2 atom of BI03 ligand.
using the available structural data of the BVDV virus envelope
protein E2. Initially, several chemical filters were applied on the
chemical libraries to remove pan assay interference compounds
(PAINS) (Baell and Holloway, 2010), compounds containing
inorganic atoms, unwanted functionalities, reactive groups, and
compounds having (i) MW <500 Dalton; (ii) more than one
violation or the Lipinsky rules (Lipinski et al., 1997), or (iii)
more than two violation of the rule of three, or more than
six #STARS using the program QikProp (Jorgensen, 2005). The
#stars parameter indicates the number of property descriptors
computed by QikProp that fall outside the optimum range of
values for 95% of known drugs.
The selected molecules were subjected to independent
parallel HTD cycles and the top 1,000 scoring compounds
were further analyzed. To ensure diversity, these highly ranked
compounds were clustered based on chemical similarity using
ICM. For each cluster, several compounds were selected
manually based on commercial availability, synthetic tractability
for potential modifications, interaction with binding site
amino acids and adequate pharmacological characteristics for
drug candidates. Finally, 19 compounds were purchased
from vendors (1–10) or synthesized (11–16), and then
evaluated in a reporter-based assay for antiviral activity
(Figure 1, Table 1). Compounds 5 and 17 were obtained
via reaction of the corresponding amine and dicyandiamide
under acidic conditions to give the required phenylbiguanide
(5, 17) in high yields. 2-Guanidinobenzimidazole (12) was
prepared by the cyclocondensation of o-phenylendiamine
with cyanoguanidine (Scheme S1 of Supplementary
Material) according to the method reported by King
et al. (1948). Synthesis of new compounds is shown in
Scheme 1. Compound (11) was obtained by ccondensation
of thiosemicarbazide with 4-(dimethylamino)benzaldehyde.
Compounds 14–16 were prepared by acylation of the
corresponding amine with the adequate carboxilic acid
chloride (15, 16) or by reaction with succinic anhydride (14) (see
Scheme 2).
First, we assayed selected compounds for cytotoxicity in
cultured cells. Only compound 6 displayed high toxicity and was
discarded from further analysis (Table 1). The remainder of the
compounds were evaluated for antiviral activity in a reporter-
based assay using a recombinant BVDV virus carrying GFP on
its genome to infect MDBK cells (Pascual et al., 2018). Expression
of GFP induced by BVDV infection was measured 2 days after
infection using flow cytometry. Inhibition of BVDV infection
was assessed by comparing the number of GFP positive cells
in non-treated control cells and in cells treated with increasing
amounts of compound. Structurally different compounds 4, 8,
11, BI03, and PTC12 showed activity with IC50 values of 30.1,
20.2, 23.9, 17.6, 0.30µM, respectively, and no cytotoxicity was
detected at 50µM. In accordance with targeting of envelope
protein function, we have previously shown that compounds
BI03 and PTC12 specifically block BVDV cell entry (Pascual et al.,
2018).
Analysis of Binding Determinants Using
Molecular Dynamics
To further characterize the likely interaction between the new
molecules and protein E2, we performed 100 ns MD simulation
on the most active compounds listed on Table 1. The docked
poses of the ligands within the binding site between domains I
and II were used as the initial conformations. For compound 8
two conformationally different poses with very similar docking
scores were used as starting conformations, and the most
probable pose was assigned based on the molecular dynamics
simulation results and the analysis of interactions (Liu and
Kokubo, 2017). The protein and ligands remained stable in
every simulation (Figure S1), displaying the ligands the following
RMSF values: PCT12, 0.4 Å; BI03, 0.4 Å; 8, 0.3 Å; 11, 0.2 Å.
The analysis of the binding determinants of the most active
compounds is described in the following paragraphs.
The predicted binding mode of PTC12 within the E2 protein
is shown in Figures 2, 3. The 3,4-dimethoxybenzamide group
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remained exposed to the solvent, whereas the thiophene ring
made contacts with Asp91, Thr60, and Arg61. The system
also presented a strong hydrogen bond between the benzamide
group of the ligand and the carbonyl O of Gln89, exhibiting
an interatomic distance of ∼2 Å and an angle of 160◦ during
the last 50 ns simulation (Figure 4). A moderate hydrogen bond
between the NH of the thiophencarboxamide and the carbonyl
O Gln89 was detected, with interatomic distances and angles
closer to 2.5 Å and 140◦, respectively. This group was also
intermittently exposed to the solvent through a narrow channel.
A stable cation-pi interaction between the aromatic ring of the 3,
4 dimethoxyphenyl group and Arg154 was observed throughout
the simulation, with a N+-ring centroid distance below 6 Å at all
times and a favorable θ angle below 40◦ during half of the last 50
ns simulation (Marshall et al., 2009).
The predicted interaction of BI03 is shown in Figure 3. This
ligand also presented a strong hydrogen bond between N2 and
the backbone amide H of Thr60, with an average interatomic
distance of 2.1 Å (Figure 4) and an angle of ∼165◦ during the
final half of the simulation. A stable cation-pi interaction was also
found in this case between the ligand ring and Arg154, showing
again distances and θ angles below 6 Å and 40◦, respectively for
most of the final 50 ns of the simulation. A moderate hydrogen
bond was also formed between the ring and the HO atom of
Thr60. The system was further stabilized by close contacts with
Thr60, Gln87, Arg154, Val153, and Pro105, while the ligand ring,
NH and OH groups were mainly exposed to the solvent.
Compound 11 is shown within its predicted binding site
in Figure 3 Two stable hydrogen bond occurred between
the HN atoms of the ligand and the carbonyl O atom in
Val153 and Gln87. In both cases interatomic distances and
angles were very favorable with average values of 2 Å and
155◦ respectively. The cation-pi interaction between Arg154
and the aromatic ring of 4-trifluoromethylphenyl group was
less favorable than for the other compounds showing higher
N+-ring centroid distances and θ angles, probably due to
a moderate interaction between the CF3 group and the
charged portion of Arg154. The ligand made contacts with
Asp91, Arg61, Arg154, Gln87, Val153, Pro105, and Thr60
while the CF3 and NMe2 groups were mostly exposed to the
solvent.
The predicted binding mode of compound 8 is shown in
Figure 3. This pose was selected as the most probable one based
on the analysis of the interactions and binding free energy
estimations. In the last half of the simulation, a moderate
hydrogen bond between N1 (N with no H) and the side chain of
Arg154 was observed, with average interactomic distances of 2.5
Å and angles of∼140◦. No cation-pi interaction was detected, and
the charged portion of Arg154 seemed to interact strongly with
the amide group of the ligand. The 3-chloro-4-fluorobenzamide
remained exposed to the solvent and there were close contacts
of the ligand with Ser57, Thr60, Gln87, Gln89, Pro105, and
Arg154.
Overall, molecular dynamics simulations reveal a common
pattern of interactions with the binding site in E2. Taken together
with previous studies on the mode of action (Pascual et al., 2018),
our data support binding of active compounds to E2. Further
studies including in vitro binding to the recombinant protein
are still required to confirm the interaction of active compounds
with E2.
CONCLUSIONS
We have undertaken a structure-based virtual screening
approach to identify small-molecules that dock into the
druggable binding site at the interface between domains I and
II of the E2 of BVDV, a virus responsible of both acute and
persistent infections in cattle, with the consequent financial
losses to the livestock industry each year. Around a million
compounds were screened, and after chemical clustering, the top
nineteen lead candidates were selected, and either purchased or
synthesized, and evaluated in a reporter-based assay for antiviral
activity. Five of these compounds exhibited IC50 values in the
low micromolar range. The likely binding determinants of these
compounds is supported by molecular dynamics simulations,
where a common pattern of interaction with the binding site in
E2 could be identified. These findings should benefit the design
of novel and improved BVDV antivirals.
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